- Report
- February 2026
- 250 Pages
Global
From €4166EUR$4,490USD£3,475GBP
- Report
- January 2026
Global
From €4547EUR$4,900USD£3,793GBP
- Report
- September 2026
- 189 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- February 2026
- 250 Pages
Global
From €4166EUR$4,490USD£3,475GBP
- Report
- November 2025
- 182 Pages
Global
From €4176EUR$4,500USD£3,483GBP
- Report
- May 2026
- 154 Pages
Global
From €3665EUR$3,950USD£3,057GBP
- Report
- November 2025
- 150 Pages
Global
From €4500EUR$4,850USD£3,754GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$4,041USD£3,022GBP
- Report
- November 2021
- 222 Pages
Global
From €2784EUR$3,000USD£2,322GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,078USD£1,554GBP
- Report
- July 2022
- 165 Pages
Global
From €5521EUR$5,950USD£4,605GBP
- Report
- March 2024
- 200 Pages
Global
From €3851EUR$4,150USD£3,212GBP
- Report
- July 2023
- 145 Pages
Global
From €2923EUR$3,150USD£2,438GBP
- Report
- November 2023
- 81 Pages
Germany
From €3248EUR$3,500USD£2,709GBP
- Report
- November 2023
- 90 Pages
France
From €3248EUR$3,500USD£2,709GBP
- Report
- October 2023
- 81 Pages
Japan
From €3248EUR$3,500USD£2,709GBP
- Report
- October 2024
- 87 Pages
Spain
From €3248EUR$3,500USD£2,709GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €2784EUR$3,000USD£2,322GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4639EUR$5,000USD£3,870GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4639EUR$5,000USD£3,870GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more